# A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction

> **NCT04855201** · PHASE1 · TERMINATED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 31 (actual)

## Conditions studied

- Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction

## Interventions

- **DRUG:** Bocidelpar
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04855201
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-14
- **Primary completion:** 2022-12-16
- **Final completion:** 2022-12-16
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Lack of Pharmacological effect
- **Last updated:** 2025-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04855201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04855201, "A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04855201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*